We’re off for another day of the J.P. Morgan Healthcare Conference. We saw a clamor of research collaboration announcements that defined the first two days of the conference. Now, those announcements have slowed, but there’s plenty of action to come as companies make their pitches to their peers, investors and industry watchers.

Roche has launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps.

Smart device maker Withings inked a deal to buy Impeto Medical, a developer of sensors for detecting potential nerve damage, which the companies plan to incorporate into a range of home-focused tech.

Less than a year after debuting its Wirion embolic protection system, Cardiovascular Systems is recalling all of the devices manufactured and distributed between January and November 2021.

Once as improbable an idea as seeing pigs fly, the xenotransplantation of organs from animals to humans is becoming an increasingly viable option as the science of genetic editing improves and organ donor waitlists continue to lengthen.

Dexcom provided a look at new data for the upcoming generation of its continuous glucose monitoring sensor. Presenting at the J.P. Morgan Healthcare Conference, the details were pulled from a large clinical study as the company awaits the FDA’s blessing.

Amicus Therapeutics is moving on from an early-phase Batten disease program after follow-up data showed the therapy didn’t stop the fatal nervous system disease from progressing long-term.

With a sneak peek at the DNA sequencing giant’s upcoming annual earnings report, Illumina announced it would post a new revenue record after sailing past the expectations it set at the start of 2021 by more than half a billion dollars.

Insulin has been the primary way of treating diabetes and other high blood sugar conditions for nearly a century. Now, researchers say a molecule made in fat tissue could pave the way for new diabetes therapies and spark new metabolism research.

Blood clotting can lead to life-threatening heart attacks and strokes, and current treatments can lead to excessive bleeding and other worrisome side effects. But researchers now say they’ve found a pathway that could open a target for new drugs.